COVID-19 saw companies target vaccines and therapies to tackle the disease, but the focus is back on non-COVID-19 drugs, particularly on cell and gene therapies and immuno-oncology, says Sanjay Vyas, Parexel's executive vice president, managing director India & global SBU head-clinical trial supplies & logistics.
Parexel Exec Says Non-COVID-19 Drug Discovery Back With A Bang
Block Chain Use Could Aid Trials
Clinical trial initiations in cell and gene therapies and immuno-oncology are seeing a spike as the COVID-19 experience has shown the benefits of beginning research early, Parexel’s executive vice president says. In an interview with Scrip, Sanjay Vyas discusses a range of topics from diversity to the advantages of block chain and growth in China
More from R&D
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
More from Scrip
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.